Pharmaceuticals: The Deregulation Catalyst — Why Non-Essential Drugs Are Now Essential for Your Portfolio
SRO 1350 opened the floodgates for pricing freedom. Here's what it means for SEARL, GLAXO, and the broader pharma index.
For decades, Pakistan's pharmaceutical sector operated under one of the most restrictive drug pricing regimes in the developing world. The Drug Regulatory Authority of Pakistan (DRAP) controlled the maximum retail price (MRP) of drugs through a classification system — 'essential' drugs (Schedule I) facing hard price caps, and 'non-essential' drugs (Schedule II) nominally more flexible but in practice constrained by bureaucratic approval timelines that lagged inflation by 3–5 years. SRO 1350 of 2025 fundamentally rewrote this dynamic for Schedule II.
What SRO 1350 Actually Does
- Schedule II (non-essential) drugs can now be priced freely by manufacturers without DRAP pre-approval
- Annual price increases for Schedule II products are permitted up to CPI+3%, without individual product filings
- DRAP retains oversight authority but shifts to ex-post review rather than pre-approval — a fundamentally faster process
- Schedule I (essential drugs) pricing remains controlled; approximately 600 molecules remain under hard caps
Pakistan's pharmaceutical sector has approximately 62,000 registered drug formulations. Roughly 70% by product count — but only 40% by revenue — fall under Schedule II and are now freely priceable under SRO 1350.
Why This Is a Structural Earnings Inflection
Pakistan's pharmaceutical manufacturers have been operating with gross margins compressed to 30–35% — well below Indian and regional peers at 50–60% — primarily because input costs (APIs, packaging, utilities) were rising with inflation while output prices were frozen. SRO 1350 allows companies to pass through accumulated cost inflation on ~70% of their product portfolio immediately, and then maintain margins going forward.
The earnings impact is front-loaded: companies that immediately reprice Schedule II products in H1 FY26 will show a step-change in gross margins that consensus forecasts, built on the old pricing regime, do not fully capture.
Company-Level Impact
| Company | Schedule II Exposure | Key Products | Estimated Margin Uplift |
|---|---|---|---|
| SEARL | ~65% of revenue | Panadol, branded generics | +400–600bps gross margin |
| GLAXO | ~55% of revenue | Consumer health, vaccines | +300–450bps gross margin |
| FEROZ | ~70% of revenue | Branded generics, OTC | +500–700bps gross margin |
| HINOPAK | ~40% of revenue | Essential drug focus | +150–250bps gross margin |
Export Growth Overlay
Pakistan's pharmaceutical exports are growing at 18% YoY as the sector establishes GMP-compliant manufacturing footprints targeting the WHO pre-qualification pathway. Export-focused revenue is priced in USD, providing a natural hedge against PKR depreciation while domestic pricing reforms protect local margins. SEARL and ICI Pakistan are the most prominent exporters to watch.
Risks
- Regulatory reversal: Government pressure on essential medicines pricing could expand Schedule I — a risk if inflation stays elevated
- API import dependency: ~80% of active pharmaceutical ingredients are imported; PKR depreciation raises input costs
- Price competition: Deregulation also allows generics manufacturers to price aggressively — branded premium could compress if substitution accelerates
- DRAP enforcement: Ex-post review is new territory for DRAP — interpretation risk remains until case law develops
⚠ This content is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.